文献速递母胎医学

母体血浆大规模蛋白组学分析发现胎儿死亡新标志物

New biomarkers for the detection of fetal death derived from large-scale proteomic analysis of maternal plasma.
PubMed 文献 · Am J Obstet Gynecol · 2026-04-02

本研究为回顾性病例对照研究,纳入38例胎儿死亡病例和23例正常妊娠对照,采集20–41周母体血浆,使用适配体多重检测测量超过7000种蛋白。结果显示,在胎盘生长因子和可溶性fms样酪氨酸激酶1基础上加入最多50个额外蛋白后,区分胎儿死亡与对照的曲线下面积从72%提升至86%。糖蛋白激素α亚基、DNAJB9和POLR3K是改善鉴别能力的前三位候选蛋白。

要点

  • 糖蛋白激素α亚基、DNAJB9与POLR3K是改善胎儿死亡鉴别的前三位候选蛋白。
  • 在胎盘生长因子和sFlt-1基础上加入额外蛋白可将AUC从72%提升至86%。
  • 胎儿死亡与子痫前期蛋白组学特征相关但存在不同扰动通路。

核心结论

  • 新的母体血浆蛋白可在已知标志物基础上改善胎儿死亡与正常对照的区分能力。
  • 胎儿死亡蛋白组学特征与子痫前期相关,但胎儿死亡不仅代表更严重的疾病状态,还涉及不同的扰动通路。

研究设计与样本

  • 回顾性病例对照研究,纳入38例胎儿死亡病例和23例无并发症妊娠对照。
  • 病例在诊断时(孕20–41周)采集血浆,对照在常规产检中按孕龄匹配采集。
  • 采用适配体多重检测法测量超过7000种蛋白分析物的丰度。
  • 采用线性模型校正采血孕龄,以校正P值<.1且倍数变化>1.25为差异显著标准。
  • 使用随机森林模型经交叉验证区分胎儿死亡病例与对照。

主要发现

  • 7146项蛋白检测中97项(1.4%)对应87个独特蛋白在胎儿死亡组与对照组间存在显著丰度差异。
  • 87个差异蛋白中63个(72%)在胎儿死亡组中丰度降低,24个(26%)丰度升高。
  • 随机森林模型联合胎盘生长因子和可溶性fms样酪氨酸激酶1的AUC为72%,再纳入最多50个额外蛋白后AUC升至86%,DeLong检验P=.004。
  • 点估计灵敏度从53%升至74%,两种情况的假阳性率均约为10%。
  • 糖蛋白激素α亚基、DnaJ同源亚家族B成员9和DNA指导的RNA聚合酶III亚基RPC10是改善区分能力的前三位候选蛋白。

关键数值与推荐

  • 差异蛋白筛选标准为校正P值<.1且倍数变化>1.25。
  • 胎盘生长因子与可溶性fms样酪氨酸激酶1联合模型的AUC为72%。
  • 胎盘生长因子与sFlt-1加最多50个额外蛋白的模型AUC为86%,DeLong检验P=.004。
  • 点估计灵敏度在加入额外蛋白后从53%提升至74%,假阳性率约10%。

临床怎么用

  • 糖蛋白激素α亚基、DNAJB9和POLR3K可作为未来改善胎儿死亡风险分层的候选标志物进一步验证。
  • 当前模型尚不能直接用于临床预测胎儿死亡,样本采集于诊断时而非预测时点。

局限性

  • 本研究不能确定这些标志物能否在胎儿死亡发生前进行前瞻性预测。
  • 样本采集于诊断当时,存在疾病状态与标志物变化之间的时间偏倚。
  • 样本量较小,病例组38例,对照组23例。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Normal pregnancy involves the modulation of thousands of maternal plasma proteins, and protein values not within the normal range may indicate the development of adverse pregnancy outcomes. A decrease in placental growth factor and an increase in soluble fms-like tyrosine kinase 1 in maternal plasma were shown to be associated with fetal death at the time of diagnosis and to predict this devastating pregnancy outcome at 24 to 28 weeks of gestation. However, these proteomic dysregulations are also present in other obstetrical syndromes, and more specific and sensitive biomarkers are needed to implement preventive strategies. OBJECTIVE: This study aimed to identify candidate protein biomarkers that can improve the prediction of fetal death relative to placental growth factor and soluble fms-like tyrosine kinase 1. STUDY DESIGN: This retrospective case-control study included 38 patients who experienced fetal death (cases) and 23 patients with uncomplicated pregnancies (controls). Plasma samples were collected at the time of diagnosis (20-41 weeks of gestation) from cases and during routine care from gestational age-matched controls. An aptamer-based multiplex assay was used to measure the abundance of >7000 protein analytes. Differential protein abundance was assessed using linear models with adjustment for gestational age at sample collection. Significance was inferred using a moderated t test adjusted P value of <.1 and a fold change of >1.25. Hypergeometric tests were performed to identify gene ontology biological processes enriched among proteins with significant changes in abundance. Random forest models were trained and evaluated via cross-validation to distinguish between fetal death cases and controls and to pinpoint the most salient predictors. RESULTS: Among the 7146 protein assays tested, 97 assays (1.4%) corresponding to 87 unique proteins differed significantly in abundance between fetal death cases and controls: 63 of 87 proteins (72%) were less abundant in fetal death cases, and 24 of 87 proteins (26%) were more abundant in fetal death cases. Dysregulated proteins were involved in pregnancy-related processes, such as angiogenesis and lactation. Random forest models effectively differentiated fetal death cases from controls, achieving an area under the receiver operating characteristic curve of 72% for the combination of placental growth factor and soluble fms-like tyrosine kinase 1, which increased to 86% when up to 50 additional proteins were included in the models (Delong test: P=.004). In addition, the point estimate of sensitivity increased from 53% to 74% (false-positive rate of approximately 10% for both). Glycoprotein hormones alpha chain (CGA), DnaJ homolog subfamily B member 9 (DNAJB9), and DNA-directed RNA polymerase III subunit RPC10 (POLR3K) emerged as the top 3 candidates to improve discrimination relative to placental growth factor and soluble fms-like tyrosine kinase 1. The significant proteomic changes in a subset of fetal death cases diagnosed first with preeclampsia relative to controls were highly correlated (r=0.78; P<.001) with those reported in late preeclampsia cases leading to live births. On average, for each 2-fold change in protein abundance in late preeclampsia leading to live birth, there was an 8.6-fold change in preeclampsia leading to fetal death. Despite this overall correlation, transcobalamin 2, glucose-6-phosphate 1-dehydrogenase, and hepcidin, among others, demonstrated dysregulation only in preeclampsia leading to fetal death, suggesting both shared and distinct pathways perturbed in the 2 syndromes. CONCLUSION: Our findings suggest that new maternal plasma proteins improve the discrimination of fetal death from controls relative to known biomarkers and that, although the signatures of fetal death and of preeclampsia are correlated, fetal death not only represents a much heightened disease state but also involves distinct perturbed pathways. Future studies are needed to determine whether the biomarkers can predict fetal death.

来源:Am J Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Romero, Bhatti, Chaiworapongsa, et al. New biomarkers for the detection of fetal death derived from large-scale proteomic analysis of maternal plasma. Am J Obstet Gynecol. 2026. PMID: 41935727. doi:10.1016/j.ajog.2026.03.029

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。